ESR1 and prostate carcinoma: Different theories suggest that castration-resistant prostate cancers have developed mechanisms that enable them to use steroids from the circulation more efficiently through de novo androgen synthesis, changed function of the androgen receptor, or even through estrogen receptor signaling pathways (21, 22, 28).